Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING LLC
Ampronix

MRI Guidance Used in Brain Cancer Drug Injection Procedure

By Medimaging International staff writers
Posted on 19 Aug 2013
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Neurosurgeons in California are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors. Using MRI navigational technology, neurosurgeons can inject Toca 511 (vocimagene amiretrorepvec), a unique investigational gene therapy, directly into a brain tumor. This new application offers a precise way to deliver a therapeutic virus designed to make the tumor vulnerable to cancer-killing drugs.

“With chemotherapy, just about every human cell is exposed to the drug’s potential side-effects. By using the direct injection approach, we believe we can limit the presence of the active drug to just the brain tumor and nowhere else in the body,” said Clark Chen, MD, PhD, chief of stereotactic and radiosurgery and vice-chairman of neurosurgery University of California (UC) San Diego School of Medicine (USA). “With MRI, we can see the tumor light up in real time during drug infusion. The rest of the brain remains unaffected so the risk of the procedure is minimized.”

Toca 511 is a retrovirus engineered to selectively replicate in cancer cells, such as glioblastomas. Toca 511 generates an enzyme that converts an antifungal drug, flucytosine (5-FC), into the anticancer drug 5-fluorouracil (5-FU). After the injection of Toca 511, the patients are treated with an investigational extended-release oral formulation of 5-FC called Toca FC. Cancer cell killing takes place when 5-FC comes into contact with cells infected with Toca 511.

“Inevitably, almost all glioblastoma patients fail currently available therapy. The challenge, in part, is knowing if current drugs are actually penetrating the tumor. This MRI-guided approach will help us deliver this drug into the tumor directly to see if the drug is working,” said Santosh Kesari, MD, PhD, lead investigator and director of neuro-oncology at UC San Diego Moores Cancer Center (USA). “This approach may lead to new treatment options for patients battling several other types of brain cancers.”

Earlier research using gene therapy to treat brain cancer was mostly limited by the failure in delivering the drug into the brain. Under normal conditions, the brain is protected by the blood-brain barrier but this natural defense mechanism also prevents drugs from reaching the cancer cells in patients with brain tumors. Fortunately, 5-FC crosses the blood-brain barrier, and direct injection of Toca 511 into the tumor provides a means to selectively generate chemotherapy within the tumor mass.

To ensure that the adequate amount of Toca 511 is delivered to the region of the tumor, neurosurgeons at UC San Diego Health System utilize state-of-the art MRI guidance, called ClearPoint, to track the delivery and injection processes in real time. The MRI-guided process provides visual validation that the desired amount of drug is delivered into the tumor and provides physicians the ability to make adjustments to optimize the location of drug delivery. The Clearpoint technology was developed by MRI Interventions (Memphis, TN, USA).

Participants in this clinical trial must be 18 years or older; have a single, recurrent Grade 3 or 4 glioma; and have had prior surgery, radiation, and chemotherapy. The MRI-based procedure is minimally invasive and all participants of the study were discharged from the hospital one day after surgery and resumed their normal daily activity.

The phase 1 trial is evaluating the safety and tolerability of Toca 511 in combination with Toca FC (5-FC, extended-release tablets), and is being developed by Tocagen, Inc. (San Diego, CA, USA).

Related Links:

University of California, San Diego Moores Cancer Center
Tocagen
MRI Interventions



Channels

Radiography

view channel

Pioneer in Orthopedic Imaging to Provide Novel Online 3-D Modeling Service for Hospitals

A company that pioneered 2-D/3-D orthopedic medical imaging has announced a new personalized 3-D image modeling service using stereo-radiographic patient images, for hospitals and healthcare professionals worldwide. The service will be able to generate 3-D models, and related clinical data, to support therapeutic decision... Read more

Ultrasound

view channel
Image: World’s first 29 MHz micro-ultrasound system (Photo courtesy of Exact Imaging).

Breakthrough High-Resolution Micro-Ultrasound Platform for the Prostate Revealed at AUA 2015

A novel micro-ultrasound imaging platform has been introduced at the annual meeting of the American Urological Association (AUA) 2015 (New Orleans, LA, USA). The probe operates at 29 MHz, and enables... Read more

Nuclear medicine

view channel
Image: PET scan images (Courtesy of King’s College London).

Preventing Unnecessary Radiotherapy for Patients with Early-Stage Hodgkin’s Lymphoma

A new study suggested that patients with early-stage (stage 1a or 2a) Hodgkin’s lymphoma disease, who underwent three cycles of chemotherapy with the drugs doxorubicin, bleomycin, vinblastine, and dacarbazine... Read more

General/Advanced Imaging

view channel

Global Healthcare Study of Coronary Artery Disease Reaches Significant Milestone

A major milestone has been reached in the Lipid-Rich Plaque (LRP) study, a prospective, multicenter clinical trial with the potential to reveal breakthrough correlations between Lipid-Rich Plaques and occurrence of heart attacks. The LPR study has now enrolled 1,000 patients, and aims to identify a correlation between... Read more

Imaging IT

view channel
Image: Clinical Collaboration Platform (Photo courtesy of Carestream Healthcare).

New, Advanced Medical Imaging and Healthcare IT Products Showcased in HIT Expo in Paris

A medical imaging systems and Information Technology (IT) solutions provider has demonstrated its advanced imaging IT platform and product updates at Health-IT (HIT) Expo 2015 on May 19–21, in Paris (France).... Read more

Industry News

view channel

Advanced Medical Imaging Startup Company Receives Venture Funding

Zebra Medical Vision (Kibbutz Shfayim, Israel) has received an USD 8 million investment from Khosla Ventures (Menlo Park, CA, USA) to double its team, set up headquarters in the US and increase its scope of work to integrate data from additional Health Maintenance Organizations (HMO). Zebra Medical has already partnered... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.